Page last updated: 2024-08-24

ibandronic acid and Breast Cancer

ibandronic acid has been researched along with Breast Cancer in 101 studies

Research

Studies (101)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	11 (10.89)	18.2507
2000's	59 (58.42)	29.6817
2010's	29 (28.71)	24.3611
2020's	2 (1.98)	2.80

Authors

Authors	Studies
Belau, A; Graf, H; Hofmann, M; Huober, J; Jackisch, C; Just, M; Krocker, J; Loibl, S; Nekljudova, V; Nitz, U; Reimer, T; Runnebaum, I; Schmatloch, S; Schmidt, M; Stickeler, E; Untch, M	1
Abrams, JS; Barlow, WE; Chew, HK; Clemons, M; Dakhil, SR; Dammann, KZ; Dees, EC; Elias, AD; Falkson, CI; Gralow, JR; Hayes, DF; Hershman, DL; Hortobagyi, GN; Ingle, JN; Lew, DL; Livingston, RB; M'iao, JL; Margolis, JH; Messino, MJ; Paterson, AHG; Schubert, MM; Stopeck, AT; Van Poznak, CH	1
Bauerfeind, I; Conrad, B; du Bois, A; Elling, D; Fehm, T; Harbeck, N; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Schneeweiss, A; Tesch, H; Thomssen, C; Untch, M; von Minckwitz, G	1
Espey, R; Grimes, S; Heyburn, G; Kealey, WD	1
Becherini, C; Bernini, M; Bianchi, S; Cecchini, S; De Feo, ML; Delli Paoli, C; Desideri, I; Francolini, G; Livi, L; Meattini, I; Nori, J; Orzalesi, L; Saieva, C; Salvestrini, V; Sanchez, L; Scotti, V; Visani, L	1
Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G	1
Ben-Aharon, I; Rizel, S; Shpilberg, O; Stemmer, SM; Sulkes, A; Vidal, L; Yerushalmi, R	1
Barrett-Lee, P; Fenlon, D; Griffiths, G; Harrop, E; Hood, K; Morris, J; Murray, N; Nelson, A; Sampson, C; Wheatley, D	1
Brown, J; Fullarton, JR; Palmieri, C	1
Costa, L	1
Abraham, J; Barrett-Lee, P; Casbard, A; Coleman, R; Grieve, R; Griffiths, G; Hood, K; Murray, N; Simmonds, P; Timmins, H; Wheatley, D	1
Felsenberg, D; Gabbert, TI; Hoffmeister, B	1
Bray, C; Canney, P; Hannon, RA; Hopkins, C; Lewsley, LA; Macpherson, IR; Ritchie, DM	1
Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S	1
Bohlmann, MK; Luedders, DW; Rody, A; Steinhoff, J; Thill, M	1
Cormack, FC; Gralow, JR; Jia, N; Najafian, B; Shiue, Z; Xie, B	1
Jiang, Z; Song, S; Tian, J; Wang, R; Wang, T; Zhang, S	1
Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R	1
Armonis, BN; Migliorati, CA; Nicolatou-Galitis, O	1
Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R	1
Georgopoulou, AP; Hatzopoulos, A; Heras, P; Kritikos, K	1
Bivi, N; Bonetti, A; Clarke, I; Delneri, D; Harrison, R; Hoyle, DC; Moro, L; Ortolani, F; Quadrifoglio, F; Romanello, M; Tell, G	1
Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K	1
Grieve, RJ; Hamilton, E; Hickish, T; Houston, S; Percival, F	1
Bergner, R; Diel, IJ; Kurth, AH; Maasberg, M; Meden, H; Sandermann, A; Sittig, HB	1
Biti, G; Bruni, A; Cipressi, S; De Luca Cardillo, C; Galardi, A; Livi, L; Meattini, I; Scotti, V	1
Hatzopoulos, A; Heras, P; Heras, V; Karagiannis, S; Kritikos, K; Kritikos, N	1
Aapro, MS	1
Angst, R; Caspar, CB; Inauen, R; Schmieding, K; Steiner, R; Thürlimann, B; von Moos, R	1
Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K	1
Abadie-Lacourtoisie, S; Dür, C; Frimat, L; Lefeuvre, C; Letessier, S; Lortholary, A; Mefti-Lacheraf, F; Morvan, P; Pivot, X; Pujade-Lauraine, E	1
Budischewski, K; du Bois, A; Jackisch, C; Kaufmann, M; Loibl, S; Lux, MP; Maass, N; Nestle-Kraemling, C; Paepke, S; Schmutzler, R; Vescia, S; von Minckwitz, G; Wallwiener, D	1
Aktas, B; Goldnau, C; Heubner, M; Hoffmann, O; Kasimir-Bauer, S; Kimmig, R; Oberhoff, C	1
Correa, PD; Han, S; Rizwanullah, M; Shrimali, RK	1
Altundag, K; Dizdar, O; Eralp, Y; Karahoca, M; Komurcu, S; Kuzhan, O; Ozguroglu, M; Ozkok, S; Ozsaran, Z; Saip, P	1
Berger, C; Karlic, H; Klaushofer, K; Spitzer, S; Thaler, R; Varga, F	1
Hiraga, T; Michigami, T; Mundy, GR; Niewolna, M; Nishimura, R; Williams, PJ; Yoneda, T	1
Bergström, B; Body, JJ; Budde, M; Diel, IJ; Dornoff, W; Gorbunova, VA; Kreuser, ED; Lichinitser, MR	2
Westermann, AM	2
Bell, R; Bergstrom, B; Body, JJ; Diel, IJ; Lazarev, A; Lichinitzer, M; Pecherstorfer, M; Tripathy, D	1
Adwan, H; Bäuerle, T; Berger, MR; Elazer, V; Golomb, G; Najajreh, Y	1
Rizzoli, R	1
Apffelstaedt, J; Bergstrom, B; Budde, M; Lazarev, A; Lichinitzer, M; MacLachlan, SA; Tripathy, D	1
Kurth, AH	1
Bell, R; Bergström, B; Body, JJ; Diel, IJ; Lazarev, AF; Lichinitser, MR; Pecherstorfer, M; Tripathy, D	1
Büyükçelik, A; Utkan, G; Yalçyn, B	1
Diel, IJ; Pecherstorfer, M	1
Body, JJ; Diel, I; Tripathy A, D	1
Body, JJ; Heidenreich, A; Ohlmann, C	1
Bell, R; Coleman, R; Heidenreich, A	1
Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U	1
Harvey, HA	1
Bian, SG; Jiang, ZF; Li, LQ; Song, ST; Wang, T; Wang, YJ; Zhu, J	1
Coleman, RE	1
Bergström, B; Body, JJ; Tripathy, D	1
Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP	2
Lipton, A	1
Gordon, DH	1
Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B	1
Bell, R	1
Body, JJ; Chaboteaux, C; Duvillier, H; Journe, F; Laurent, G; Magne, N	1
McCormack, PL; Plosker, GL	1
Franke, HR; Verdijk, R; Vermes, I; Wolbers, F	1
Bergstrom, B; Body, JJ; Diel, IJ; Tripathy, D	1
Bauss, F; Body, JJ; Chaboteaux, C; Journé, F; Kinnaert, E; Magné, N	1
Cameron, D; Diel, I; Fallon, M	1
Blair, JM; Brennan, K; Dunstan, CR; Modzelewski, JR; Seibel, MJ; Zheng, Y; Zhou, H	1
Bergström, B; Cameron, D; McLachlan, SA; Murray, R; Tripathy, D	1
Bergström, B; Body, JJ; Diel, I; Pecherstorfer, M; Rivkin, S	1
Nagykálnai, T	1
Bergström, B; Body, JJ; Garnero, P; Lichinitser, M; Tjulandin, S	1
Clemons, M; Cole, DE; Dranitsaris, G; Ooi, W	1
Quesnel, M	1
Malden, NJ; Pai, AY	1
Body, JJ; Chaboteaux, C; Duvillier, H; Journé, F; Kheddoumi, N; Laurent, G	1
Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R	1
McKeage, K; Plosker, GL	1
Angst, R; Bergstrom, B; Caspar, CB; Greil, R; Inauen, R; Pecherstorfer, M; Schmieding, K; Thürlimann, B; von Moos, R	1
Baldini, E; Barni, S; Berto, P; Cortesi, E; Dauria, G; Schivazappa, C	1
Coleman, R; Vinholes, J	1
Bauss, F; De Clerck, YA; Dunstan, C; Mundy, GR; Sasaki, A; Williams, PJ; Yoneda, T	1
Body, JJ; Buck, S; Huss, HJ; Ludwig, H; Pecherstorfer, M; Schlosser, K	1
Ziegler, J	1
Boissier, S; Clezardin, P; Cuzin, B; Delmas, PD; Ebetino, FH; Frappart, L; Magnetto, S	1
Enomoto, K	1
Burckhardt, P	1
Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD	1
Black, C; Coleman, RE; Huss, H; Kanis, J; Purohit, OP; Quinn, KJ; Schlosser, K; Vinholes, JJ	1
Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S	1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP	1
Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O	1
Body, JJ; Fromigue, O; Lagneaux, L	1
Hiraga, T; Mundy, GR; Williams, PJ; Yoneda, T	1

Reviews

22 review(s) available for ibandronic acid and Breast Cancer

Article	Year
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis. PloS one, 2013, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Female; Humans; Ibandronic Acid; Pamidronate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; Risk; Treatment Outcome	2013
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24 Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2013
Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC cancer, 2015, Jul-22, Volume: 15 Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Glomerulosclerosis, Focal Segmental; Humans; Ibandronic Acid; Prednisone; Proteinuria; Tacrolimus; Treatment Outcome	2015
Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature. Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:1 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Pain; Quality of Life	2010
Challenges in clinical patient management. Cancer investigation, 2010, Volume: 28 Suppl 1 Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis; Risedronic Acid; Tamoxifen	2010
Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2004, Volume: 12, Issue:12 Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Injections, Intravenous; Kidney Diseases	2004
Ibandronate reduces skeletal morbidity in patients with breast cancer. Seminars in oncology, 2004, Volume: 31, Issue:5 Suppl 10 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Morbidity	2004
Ibandronate in metastatic bone pain. Seminars in oncology, 2004, Volume: 31, Issue:5 Suppl 10 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Pain; Urologic Neoplasms	2004
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 12 Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid	2004
Bisphosphonates in breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:5 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid	2005
Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clinical therapeutics, 2004, Volume: 26, Issue:12 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Multicenter Studies as Topic; Pain; Poisson Distribution; Randomized Controlled Trials as Topic	2004
New therapeutic agents for the treatment of bone diseases. Expert opinion on biological therapy, 2005, Volume: 5, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2005
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clinical breast cancer, 2005, Volume: 6, Issue:2 Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid	2005
Efficacy of ibandronate in metastatic bone disease: review of clinical data. The oncologist, 2005, Volume: 10 Suppl 1 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Colorectal Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Multiple Myeloma; Treatment Outcome	2005
Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs, 2006, Volume: 66, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic	2006
Ibandronate: its role in metastatic breast cancer. The oncologist, 2006, Volume: 11 Suppl 1 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Pain; Randomized Controlled Trials as Topic	2006
[The role of ibandronate in the daily oncological practice]. Magyar onkologia, 2006, Volume: 50, Issue:4 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Medical Oncology; Quality of Life	2006
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. PharmacoEconomics, 2008, Volume: 26, Issue:3 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid	2008
[New drugs in metastatic breast cancer--1997]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid	1997
Ibandronate in oncology. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Neoplasms; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic	1997
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:12 Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Multiple Myeloma; Pain; Pamidronate	1998
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid	2000

Trials

32 trial(s) available for ibandronic acid and Breast Cancer

Article	Year
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. European journal of cancer (Oxford, England : 1990), 2023, Volume: 194 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Ibandronic Acid; Middle Aged	2023
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. Journal of the National Cancer Institute, 2020, 07-01, Volume: 112, Issue:7 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate; Treatment Outcome; Zoledronic Acid	2020
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Aug-01, Volume: 28, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Dose-Response Relationship, Drug; Early Diagnosis; Epirubicin; Female; Filgrastim; Germany; Humans; Ibandronic Acid; Middle Aged; Paclitaxel; Polyethylene Glycols; Young Adult	2017
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. European journal of cancer (Oxford, England : 1990), 2019, Volume: 108 Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method	2019
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-01, Volume: 31, Issue:28 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Diphosphonates; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Ibandronic Acid; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Young Adult	2013
QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials, 2013, Oct-09, Volume: 14 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comprehension; Diphosphonates; England; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pain Measurement; Patient Preference; Patient Satisfaction; Patients; Qualitative Research; Quality of Life; Time Factors; Treatment Outcome; Wales; Zoledronic Acid	2013
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. The Lancet. Oncology, 2014, Volume: 15, Issue:1 Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Zoledronic Acid	2014
Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical breast cancer, 2015, Volume: 15, Issue:2 Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Pain; Peptides	2015
Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases. Anticancer research, 2015, Volume: 35, Issue:3 Topics: Acute Disease; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney; Middle Aged; Prospective Studies; Zoledronic Acid	2015
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Nitriles; Placebos; Triazoles	2008
Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. European journal of cancer care, 2009, Volume: 18, Issue:6 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged; Treatment Outcome	2009
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain. American journal of therapeutics, 2011, Volume: 18, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Lung Neoplasms; Male; Middle Aged; Pain; Pamidronate; Quality of Life	2011
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. Onkologie, 2010, Volume: 33, Issue:8-9 Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney; Kidney Diseases; Longitudinal Studies; Middle Aged; Treatment Outcome	2010
Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial. Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Renal Insufficiency; Treatment Outcome	2011
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011, Volume: 20, Issue:10 Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Goserelin; Hot Flashes; Humans; Ibandronic Acid; Mass Screening; Middle Aged; Premenopause; Prognosis; Risk Factors	2011
Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. Anticancer research, 2011, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antibody Specificity; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Immunohistochemistry; Middle Aged; Neoplastic Cells, Circulating; Pilot Projects	2011
Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain. Onkologie, 2012, Volume: 35, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Pain; Pain Measurement; Prospective Studies; Treatment Outcome	2012
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:9 Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Incidence; Injections, Intravenous; Treatment Outcome	2003
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Morbidity; Placebos; Risk Factors	2004
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Morbidity; Pain; Placebos	2004
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Long-Term Care; Middle Aged; Pain; Quality of Life; Survival Analysis; Treatment Outcome	2004
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain, 2004, Volume: 111, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Middle Aged; Pain; Quality of Life; Statistics, Nonparametric	2004
[Clinical trial on ibandronate in patients with tumor-associated hypercalcemia]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:12 Topics: Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Hypercalcemia; Ibandronic Acid; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Phosphorus; Pruritus	2004
S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Predictive Value of Tests; Survival Rate; Zoledronic Acid	2005
Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. European journal of cancer care, 2006, Volume: 15, Issue:3 Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Diseases; Middle Aged; Time Factors	2006
Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience. Clinical drug investigation, 2006, Volume: 26, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Ibandronic Acid; Kidney; Middle Aged	2006
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clinical drug investigation, 2006, Volume: 26, Issue:6 Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Injections, Intravenous; Leg; Middle Aged; Neoplasm Metastasis; Pulmonary Embolism; Survival Rate; Thrombosis; Time Factors; Treatment Outcome	2006
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:7 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteocalcin; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid	2007
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast cancer research and treatment, 2008, Volume: 108, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Pain; Palliative Care; Pamidronate	2008
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Function Tests; Neoplasm Metastasis; Random Allocation; Time Factors; Treatment Outcome	2008
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1996, Volume: 11, Issue:5 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged	1996
Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Area Under Curve; Biomarkers; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibandronic Acid; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome	1999

Other Studies

47 other study(ies) available for ibandronic acid and Breast Cancer

Article	Year
The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer. BMJ case reports, 2017, May-09, Volume: 2017 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Nails; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Diphosphonates; Female; Femoral Fractures; Humans; Ibandronic Acid; Middle Aged	2017
Which bisphosphonate to treat bone metastases? The Lancet. Oncology, 2014, Volume: 15, Issue:1 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Zoledronic Acid	2014
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid	2015
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. Molecular cancer, 2014, Dec-11, Volume: 13 Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid	2014
Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer. Clinical and experimental pharmacology & physiology, 2017, Volume: 44, Issue:1 Topics: Adult; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Peptides; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Treatment Outcome	2017
The use of randomisation-based efficacy estimators in non-inferiority trials. Trials, 2017, 03-09, Volume: 18, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Colitis, Ulcerative; Data Interpretation, Statistical; Diphosphonates; Female; Gastrointestinal Agents; Humans; Ibandronic Acid; Imidazoles; Intention to Treat Analysis; Male; Medication Adherence; Mesalamine; Models, Statistical; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Treatment Outcome; Zoledronic Acid	2017
Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2008, Volume: 106, Issue:1 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis	2008
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection. Genome biology, 2009, Volume: 10, Issue:9 Topics: Alendronate; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Movement; Diphosphonates; DNA Breaks, Double-Stranded; DNA Damage; Etidronic Acid; Gene Deletion; Humans; Ibandronic Acid; Microscopy, Confocal; Microscopy, Electron; Microtubules; Mutation; Polyisoprenyl Phosphates; Risedronic Acid; RNA Interference; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins	2009
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2009
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. Journal of medical economics, 2010, Volume: 13, Issue:1 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Health Care Costs; Health Resources; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney; Kidney Function Tests; Middle Aged; Renal Insufficiency; State Medicine; Zoledronic Acid	2010
Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010, Volume: 18, Issue:10 Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Pain; Prospective Studies; Severity of Illness Index	2010
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System. Clinical breast cancer, 2010, Dec-01, Volume: 10, Issue:6 Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid	2010
Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment. BMJ case reports, 2010, May-06, Volume: 2010 Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Letrozole; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Nitriles; Positron-Emission Tomography; Radiopharmaceuticals; Spinal Neoplasms; Tomography, X-Ray Computed; Triazoles	2010
Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochemical pharmacology, 2013, Jan-15, Volume: 85, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Epigenesis, Genetic; fas Receptor; Female; Gene Silencing; Humans; Ibandronic Acid; Male; Mice; Neoplasm Proteins; Osteosarcoma; Promoter Regions, Genetic; Up-Regulation	2013
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast cancer research and treatment, 2002, Volume: 75, Issue:3 Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxorubicin; Female; Heart Neoplasms; Humans; Ibandronic Acid; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Tumor Cells, Cultured	2002
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:3 Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Incidence; Infusions, Intravenous	2004
Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. International journal of oncology, 2004, Volume: 24, Issue:5 Topics: Adult; Bone Neoplasms; Breast Neoplasms; Cell Division; Cell Movement; Child; Colony-Forming Units Assay; Diphosphonates; Down-Regulation; Female; Green Fluorescent Proteins; Humans; Ibandronic Acid; Immunoglobulin G; Integrin-Binding Sialoprotein; Luminescent Proteins; Male; Oligonucleotides, Antisense; Organophosphates; Osteoblasts; Osteopontin; Osteosarcoma; Quaternary Ammonium Compounds; Sialoglycoproteins	2004
Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:5 Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Infusions, Intravenous	2004
[Oral and parenteral forms of aminobisphosphonate]. Krankenpflege Journal, 2004, Volume: 42, Issue:3-4 Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Colorectal Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Osteolysis; Spinal Neoplasms	2004
[Bone metastases in breast carcinoma. Bisphosphonate protects from complications]. MMW Fortschritte der Medizin, 2004, Apr-01, Volume: 146, Issue:14 Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Time Factors	2004
The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:10 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Treatment Outcome	2004
Targeting Breast Cancer with Care. Proceedings of a meeting. Prague, Czech Republic, February 2004. Seminars in oncology, 2004, Volume: 31, Issue:5 Suppl 10 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid	2004
Managing metastatic bone disease: three case studies. Seminars in oncology, 2004, Volume: 31, Issue:5 Suppl 10 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasms, Second Primary; Palliative Care; Prostatic Neoplasms	2004
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncology reports, 2004, Volume: 12, Issue:5 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid	2004
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3 Topics: Administration, Oral; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Ethics, Medical; Female; Humans; Ibandronic Acid; Placebos; Randomized Controlled Trials as Topic	2005
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005, Volume: 13, Issue:12 Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Metastasis; Pamidronate; Quality of Life; State Medicine; United Kingdom; Zoledronic Acid	2005
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clinical therapeutics, 2005, Volume: 27, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Quality-Adjusted Life Years; United Kingdom; Zoledronic Acid	2005
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2005, Volume: 33, Issue:6 Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid	2005
Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005. Clinical breast cancer, 2005, Volume: 6, Issue:5 Topics: Administration, Oral; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Docetaxel; Europe; Female; Humans; Ibandronic Acid; Lapatinib; Quinazolines; Taxoids; Trastuzumab	2005
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast cancer research : BCR, 2006, Volume: 8, Issue:1 Topics: Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Ibandronic Acid; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured	2006
Differential effects of bisphosphonates on breast cancer cell lines. Cancer letters, 2007, Feb-08, Volume: 246, Issue:1-2 Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid	2007
Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines. Clinical & experimental metastasis, 2006, Volume: 23, Issue:2 Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Survival; Combined Modality Therapy; Diphosphonates; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ibandronic Acid; Radiotherapy Dosage; Tumor Cells, Cultured	2006
Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone, 2007, Volume: 40, Issue:2 Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Female; Ibandronic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoprotegerin; Tibia; Xenograft Model Antitumor Assays	2007
[Nurse's role in the home management of patients with breast cancer and bone metastases]. Soins; la revue de reference infirmiere, 2007, Issue:715 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Protocols; Community Health Nursing; Diphosphonates; Drug Monitoring; Home Care Services; Home Infusion Therapy; Humans; Ibandronic Acid; Nurse's Role; Nursing Assessment	2007
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. British dental journal, 2007, Jul-28, Volume: 203, Issue:2 Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chlorhexidine; Clindamycin; Diphosphonates; Etidronic Acid; Facial Pain; Female; Humans; Ibandronic Acid; Jaw Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Penicillin V; Risedronic Acid; Tooth Extraction	2007
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. Breast cancer research : BCR, 2008, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Bone and Bones; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Synergism; Female; Humans; Ibandronic Acid; Imidazoles; Zoledronic Acid	2008
Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171). Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2 Topics: Administration, Oral; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Osteocalcin; Peptides; Procollagen; Prognosis; Sensitivity and Specificity; Zoledronic Acid	2008
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies]. Recenti progressi in medicina, 2008, Volume: 99, Issue:1 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid	2008
The management of bone metastases. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:7 Topics: Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Middle Aged; Pain	1995
[Bisphosphonates in radiotherapy]. Der Radiologe, 1997, Volume: 37, Issue:1 Suppl Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Radiotherapy	1997
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. The Journal of clinical investigation, 1997, May-15, Volume: 99, Issue:10 Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Survival; Diphosphonates; Female; Genetic Therapy; Heart Ventricles; Humans; Ibandronic Acid; Mice; Mice, Nude; Neoplasm Invasiveness; Osteolysis; Protein Biosynthesis; Tibia; Tissue Inhibitor of Metalloproteinase-2; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured	1997
Research on bone metastases quickens its pace. Journal of the National Cancer Institute, 1997, Jun-18, Volume: 89, Issue:12 Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Neoplasm Proteins; Palliative Care; Parathyroid Hormone-Related Protein; Proteins; Zoledronic Acid	1997
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer research, 1997, Sep-15, Volume: 57, Issue:18 Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhesion Molecules; Clodronic Acid; Diphosphonates; Extracellular Matrix; Female; Humans; Ibandronic Acid; In Vitro Techniques; Integrins; Male; Neoplasm Metastasis; Osteoblasts; Pamidronate; Prostatic Neoplasms; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured	1997
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. International journal of cancer, 1999, Oct-08, Volume: 83, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured	1999
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer research, 2000, Jun-01, Volume: 60, Issue:11 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid	2000
Bisphosphonates induce breast cancer cell death in vitro. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:11 Topics: Amino Acid Chloromethyl Ketones; Annexins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Death; Cell Nucleus; Clodronic Acid; Cysteine Proteinase Inhibitors; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Imidazoles; Kinetics; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid	2000
The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer research, 2001, Jun-01, Volume: 61, Issue:11 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Mice; Mice, Inbred BALB C; Osteoclasts; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001